**IJPHARMDART** ***e-ISSN: 3139-1117***
Volume 2 (4); April-2026

# PD-1 Inhibitors in Parkinson's Disease: Restoring Dopaminergic Balance

**Sagar Sahu[1], Sonam Sahu[2], Gunjan Kalyani[1]***

[1] Columbia Institute of Pharmacy, Near Vidhan Sabha,
Village – Tekari, Raipur - 493111, Chhattisgarh, India
[2] Mother Teresa College of Nursing, Near Power Grid,
Village Chorha, Kumhari - 490042, Durg, Chhattisgarh, India

**Corresponding Author's Email**: kalyani.gunjan@yahoo.in

**ABSTRACT:**
Parkinson's Disease (PD) is fundamentally characterized by the progressive loss of dopaminergic neurons in the substantia nigra, leading to a severe depletion of dopamine in the striatum and subsequent motor symptoms like tremor, rigidity, and bradykinesia. Current treatments primarily focus on restoring dopaminergic balance symptomatically, but do not halt or reverse the underlying neurodegeneration. There is growing interest in the role of neuroinflammation in PD pathogenesis and how novel immunomodulatory therapies, such as PD-1 inhibitors, might offer neuroprotective effects and contribute to restoring dopaminergic balance. It's crucial to emphasize that PD-1 inhibitors are NOT currently a recognized treatment for Parkinson's disease or dopaminergic imbalance. Existing treatments for Parkinson's disease primarily focus on replenishing dopamine (e.g., levodopa) or mimicking its effects (dopamine agonists) to manage symptoms. Therefore, this review focusses on the connection between PD-1 inhibitors and dopaminergic imbalance is an active area of scientific inquiry, particularly in understanding the role of the immune system in neurodegenerative diseases. Any therapeutic application in this context would be far in the future and require extensive preclinical and clinical validation.

**KEYWORDS:**
Parkinson's Disease, Dopaminergic Balance, PD-1 Inhibitors, Dopamine, Neurodegenerative Diseases.

**INTRODUCTION :**

Parkinson's Disease (PD) is a progressive neurodegenerative disorder that primarily affects movement. It's a complex condition that impacts not only motor skills but also a wide range of non-motor functions. The hallmark of Parkinson's disease is the degeneration and death of nerve cells (neurons) in a specific area of the brain called the substantia nigra. These neurons produce a crucial chemical messenger called dopamine. Dopamine is essential for smooth and coordinated muscle movements. When dopamine levels drop significantly, it leads to the characteristic symptoms of PD [1].

While the exact cause of neuronal death in PD is not fully understood, it's believed to be a combination of:

- Genetic factors: A small percentage of PD cases are linked to specific gene mutations.
- Environmental factors: Exposure to certain toxins or pesticides has been implicated as a risk factor.
- Presence of Lewy bodies: These are abnormal clumps of proteins, mainly alpha-synuclein, found in the brains of people with PD. Researchers believe these protein clumps play a significant role in the disease's progression.
- Neuroinflammation: Chronic inflammation in the brain is increasingly recognized as a key contributor to neuronal damage and disease progression [1].

1.1. Symptoms of Parkinson's Disease

Symptoms typically develop gradually and worsen over time. They can vary from person to person in terms of type, severity, and progression.

Primary Motor Symptoms:

- Tremor: Rhythmic shaking, often starting in a hand or finger, especially at rest (resting tremor). It may look like "pill-rolling."
- Bradykinesia (slowness of movement): This is a hallmark symptom, making everyday tasks difficult and leading to a lack of spontaneous or automatic movements (e.g., reduced facial expression, less arm swing when walking).
- Rigidity (muscle stiffness): Muscles remain tense and tight, causing aches, pain, and difficulty moving. It can lead to "cogwheel" rigidity, where movement feels jerky.
- Postural instability: Impaired balance and coordination, increasing the risk of falls.

Non-Motor Symptoms: These can often appear years before motor symptoms and significantly impact quality of life [1].

- Loss of smell (anosmia/hyposmia): A reduced or absent sense of smell.

- Sleep problems: Insomnia, restless sleep, vivid dreams, and REM sleep behavior disorder (acting out dreams).
- Constipation: Due to issues with the autonomic nervous system.
- Depression and anxiety: Common mental health challenges.
- Fatigue: Persistent and overwhelming tiredness.
- Cognitive changes: Problems with memory, attention, planning, and executive function. In later stages, some individuals may develop Parkinson's disease dementia (PDD).
- Speech changes (dysarthria): Soft, monotonous, or rapid speech.
- Swallowing difficulties (dysphagia): Can lead to choking or drooling.
- Urinary problems: Such as an overactive bladder.
- Pain.
- Orthostatic hypotension: A sudden drop in blood pressure upon standing, causing dizziness or lightheadedness.
- Skin problems: Increased facial oils (seborrhea) [1].

1.3 Diagnosis of Parkinson's Disease

Diagnosis is primarily clinical, based on a neurological examination and evaluation of symptoms. There is no single definitive test for PD. Doctors may:

- Assess motor function, coordination, reflexes, and mental abilities.
- Rule out other conditions with similar symptoms through blood tests and imaging (MRI, CT scans).
- A dopamine transporter (DAT) scan can help support a diagnosis by showing reduced dopamine activity in the brain, but it's not always necessary.
- A trial of levodopa medication to see if symptoms improve can also help confirm the diagnosis.
- Recent research is focusing on alpha-synuclein tests in spinal fluid or skin to detect the presence of the abnormal protein, potentially allowing for earlier diagnosis [1].

2. TREATMENT OF PARKINSON'S DISEASE

Currently, there is no cure for Parkinson's disease, but various treatments can help manage symptoms and improve quality of life. Treatment is highly individualized and often involves a multidisciplinary approach.

2.1 Medications

- Levodopa: The most effective medication for motor symptoms. It's converted into dopamine in the brain. Often combined with carbidopa to reduce side effects.

- Dopamine agonists: Mimic the effects of dopamine in the brain.
- MAO-B inhibitors: Prevent the breakdown of dopamine, increasing its levels.
- COMT inhibitors: Extend the action of levodopa by inhibiting its breakdown.
- Amantadine: Can help with dyskinesia (involuntary movements) that can occur as a side effect of levodopa.
- Anticholinergics: May help with tremors and dystonia (muscle spasms), though less commonly used due to side effects [1].

2.2 Surgical Therapies

- Deep Brain Stimulation (DBS): Involves surgically implanting electrodes in specific brain areas that are connected to a device (like a pacemaker) that sends electrical impulses to control movement symptoms. It's often considered for advanced PD when medication effects fluctuate or become less effective.
- Lesion surgery: Less common now, involves creating small, precise lesions in specific brain areas to disrupt abnormal brain activity [1].

2.3 Supportive Therapies and Lifestyle Modifications

- Physiotherapy: Helps improve mobility, balance, flexibility, and gait through exercises and movement techniques.
- Occupational therapy: Provides strategies and adaptive devices to help with daily living activities (e.g., dressing, eating).
- Speech and language therapy: Addresses speech difficulties (e.g., volume, clarity) and swallowing problems.
- Diet advice: Important for managing constipation, low blood pressure, and ensuring adequate nutrition.
- Exercise: Regular physical activity (walking, dancing, cycling) is crucial for maintaining strength, balance, and overall well-being.
- Mental health support: Counseling, support groups, and medication can help manage depression and anxiety [1].

2.4 Emerging Research

Research is ongoing to find new treatments that can slow, stop, or even reverse the progression of PD. This includes:

- Investigating neuroprotective agents.
- Exploring immunomodulatory therapies like PD-1 inhibitors (as discussed previously) to target neuroinflammation.
- Gene therapies and stem cell research.

- Studies into compounds like Ambroxol (a common cough medicine) showing promise in slowing cognitive decline in Parkinson's disease dementia.
- New findings on restoring copper levels in the brain to reduce Parkinson-like damage.

Living with Parkinson's disease requires a comprehensive and adaptive approach, involving medical management, therapies, lifestyle adjustments, and strong support systems for both the individual with PD and their caregivers [2].

## 3. THE ROLE OF INFLAMMATION IN PARKINSON'S DISEASE

Neuroinflammation, a sustained inflammatory response within the brain, is increasingly recognized as a crucial player in the development and progression of Parkinson's Disease (PD). While initially thought to be merely a consequence of neuronal degeneration, mounting evidence suggests that it actively contributes to the damage of dopamine-producing neurons, thereby accelerating the disease [2].

Here's a breakdown of the key aspects of inflammation's role in PD:

### 3.1 Key Players in Neuroinflammation

- Microglia: These are the brain's resident immune cells, acting as the primary line of defense. In a healthy brain, microglia maintain homeostasis, surveying the environment and clearing cellular debris. However, in PD, they become chronically activated and transition to a pro-inflammatory state. This "reactive microglia" phenotype is characterized by:
    - Release of Pro-inflammatory Mediators: Activated microglia release various harmful substances, including:
        - Cytokines: Such as Tumor Necrosis Factor-alpha (TNF-α), Interleukin-1 beta (IL-1$\beta$), and Interleukin-6 (IL-6). These signaling molecules create a toxic environment for neurons, promoting their dysfunction and death.
        - Chemokines: Which attract other immune cells to the inflamed area.
        - Reactive Oxygen Species (ROS) and Nitric Oxide (NO): These highly reactive molecules cause oxidative stress, leading to cellular damage.
    - Impaired Clearance: While microglia are normally involved in clearing misfolded proteins like alpha-synuclein, their function can become impaired in PD, leading to a build-up of these toxic aggregates.

- Propagation of Alpha-Synuclein: Some research suggests that activated microglia might also contribute to the spread of pathological alpha-synuclein aggregates throughout the brain [2].

- Astrocytes: These are another type of glial cell that support neuronal function. In PD, astrocytes can also become reactive, contributing to inflammation and potentially losing their neuroprotective capabilities. They can release pro-inflammatory factors and even become senescent (aging and dysfunctional).
- Peripheral Immune Cells: The brain is typically protected by the blood-brain barrier (BBB). However, in PD, this barrier can become compromised, allowing peripheral immune cells (like T cells and monocytes) to infiltrate the brain, further exacerbating the inflammatory response [2].

3.2 Mechanisms by which Inflammation Contributes to PD

- Direct Neuronal Toxicity: The pro-inflammatory cytokines, ROS, and NO released by activated glia can directly damage and kill dopaminergic neurons in the substantia nigra.
- Mitochondrial Dysfunction: Inflammation can lead to mitochondrial damage within neurons, impairing their energy production and making them more vulnerable to stress and death.
- Alpha-Synuclein Aggregation and Spread
  - Misfolded alpha-synuclein, a hallmark protein in PD, can directly activate microglia, forming a vicious cycle where alpha-synuclein triggers inflammation, and inflammation, in turn, may promote further alpha-synuclein aggregation and toxicity.
  - The NLRP3 inflammasome, a multi-protein complex involved in initiating inflammation, is particularly active in PD and can be activated by abnormal alpha-synuclein.
- Oxidative Stress: Chronic inflammation contributes to an increase in oxidative stress, which is a major factor in neuronal damage in PD.
- Gut-Brain Axis: There is growing evidence for a strong connection between gut inflammation and PD. Changes in the gut microbiome can trigger inflammation in the gut, which may then influence neuroinflammation in the brain, potentially through a "gut-brain axis." People with inflammatory bowel disease (IBD), for example, have an increased risk of developing PD [2].

3.3 Inflammation as a Therapeutic Target

The understanding that inflammation plays a causal role, and not just a reactive one, has opened up new avenues for therapeutic intervention in PD. The aim is to:

- Reduce Neuroinflammation: By directly targeting inflammatory pathways or modulating the activity of immune cells.
- Shift Microglial Phenotype: Encouraging microglia to adopt a more anti-inflammatory and neuroprotective role.
- Prevent Further Neuronal Loss: By creating a less hostile environment for dopaminergic neurons [3].

This is where therapies like PD-1 inhibitors (as discussed previously) and other anti-inflammatory strategies come into play, aiming to modify the disease's progression rather than just managing symptoms. Clinical trials are underway or being planned to assess the efficacy of various anti-inflammatory approaches in PD.

In summary, inflammation in Parkinson's disease is a complex and multifaceted process involving various immune cells and signaling molecules. It contributes significantly to neuronal damage and disease progression, making it a critical area of research for developing disease-modifying therapies [3].

## 4. UNDERSTANDING DOPAMINERGIC IMBALANCE IN PD

Dopaminergic imbalance is the central pathophysiological feature of Parkinson's Disease (PD) and is directly responsible for the characteristic motor symptoms. To understand this imbalance, it's crucial to grasp the normal role of dopamine in the brain and how its deficiency disrupts critical neural circuits [3].

### 4.1 The Normal Role of Dopamine in Movement

Dopamine is a neurotransmitter produced in the brain, primarily by neurons in the substantia nigra pars compacta (SNpc). These neurons project to a region called the striatum, which is a key component of the basal ganglia. The basal ganglia is a group of interconnected brain structures that play a vital role in initiating and controlling voluntary movements [3].

Within the basal ganglia, dopamine acts on two main pathways that regulate movement:

Direct Pathway: This pathway facilitates movement. When dopamine binds to D1 receptors on neurons in the striatum, it excites these neurons, ultimately leading to the initiation of movement.

Indirect Pathway: This pathway inhibits movement. When dopamine binds to D2 receptors on different neurons in the striatum, it inhibits these neurons, thereby suppressing unwanted movements.

In a healthy brain, dopamine maintains a delicate balance between these two pathways, allowing for smooth, coordinated, and purposeful movements [3].

4.2 The Dopaminergic Imbalance in PD

The fundamental problem in Parkinson's Disease is the progressive degeneration and death of dopaminergic neurons in the substantia nigra. This leads to a severe reduction in dopamine production and release in the striatum.

When dopamine levels drop significantly (typically by 60-80% before motor symptoms become apparent), the balance between the direct and indirect pathways is profoundly disrupted:

- Under-activation of the Direct Pathway: With less dopamine to excite D1 receptors, the direct pathway's ability to facilitate movement is impaired.
- Over-activation of the Indirect Pathway: With less dopamine to inhibit D2 receptors, the indirect pathway becomes overactive, excessively suppressing movement.

This imbalance results in a net inhibitory output from the basal ganglia to the motor cortex, making it difficult for individuals with PD to initiate and control voluntary movements [3].

4.3 How Dopaminergic Imbalance Leads to Motor Symptoms:

- Bradykinesia (Slowness of Movement): This is a direct consequence of the overall reduction in movement initiation and execution due to the impaired direct pathway and overactive indirect pathway. Everyday tasks become painstakingly slow and effortful.
- Rigidity (Muscle Stiffness): The increased inhibitory output from the basal ganglia leads to sustained muscle contractions, causing stiffness and a reduced range of motion. This can feel like a constant tension in the limbs or trunk.
- Tremor (Resting Tremor): While the exact mechanism is complex, the disruption in basal ganglia circuitry, particularly involving feedback loops, is thought to generate the characteristic rhythmic, involuntary shaking seen at rest.
- Postural Instability: Impaired balance and coordination arise from the difficulty in making rapid, automatic postural adjustments due to the disrupted motor control. This increases the risk of falls [3].

4.4 Beyond Motor Symptoms:

While dopamine deficiency is the primary driver of motor symptoms, it's important to note that Parkinson's disease is a complex multi-system disorder. Other neurotransmitter systems (e.g., acetylcholine, norepinephrine, serotonin) are also affected, contributing to the wide range of non-motor symptoms such as:

- Cognitive impairment
- Depression and anxiety
- Sleep disturbances
- Loss of smell
- Constipation

These non-motor symptoms can sometimes precede motor symptoms by many years, indicating that the neurodegenerative process in PD extends beyond just the dopaminergic neurons in the substantia nigra [3].

## 5. THERAPEUTIC IMPLICATIONS

Current treatments for PD primarily aim to restore dopaminergic balance symptomatically:

- Levodopa: This is the most effective medication. It's a precursor to dopamine that crosses the blood-brain barrier and is converted into dopamine by the remaining dopaminergic neurons, thus replenishing dopamine levels in the striatum.
- Dopamine Agonists: These medications directly stimulate dopamine receptors, mimicking the effects of natural dopamine.
- MAO-B Inhibitors and COMT Inhibitors: These drugs prevent the breakdown of dopamine, allowing it to remain in the brain for longer.

While these treatments are highly effective in managing motor symptoms, they do not halt the underlying neurodegeneration or address the non-dopaminergic aspects of the disease. This is why research into new therapies, such as those targeting neuroinflammation, is crucial for developing disease-modifying treatments for PD [3].

## 6. PD-1 INHIBITORS: A POTENTIAL IMMUNOMODULATORY APPROACH

PD-1 inhibitors represent a significant breakthrough in cancer immunotherapy, but their potential application as an immunomodulatory approach in neurodegenerative diseases like Parkinson's Disease (PD) is an exciting and rapidly evolving area of research. This approach hinges on the growing understanding of the crucial role of neuroinflammation in PD pathogenesis Fig. (1) [3].




**Fig. (1). PD-1 Inhibitors**

6.1 What are PD-1 Inhibitors?

PD-1 (Programmed Cell Death protein 1) is a checkpoint receptor found on the surface of T cells, a type of immune cell crucial for fighting infections and cancer. When PD-1 binds to its ligands, PD-L1 (Programmed Death-Ligand 1) or PD-L2, it acts as an "off-switch" for T cell activity [3]. This interaction normally helps to:

- Maintain immune tolerance: Preventing the immune system from attacking healthy body tissues (autoimmunity).
- Limit immune responses: Controlling the intensity and duration of immune reactions to prevent excessive inflammation.

In the context of cancer, tumor cells often overexpress PD-L1, effectively "hiding" from the immune system by engaging the PD-1 "off-switch" on T cells. PD-1 inhibitors (and PD-L1 inhibitors) are monoclonal antibodies that block this interaction. By doing so, they "release the brakes" on the T cells, allowing them to become re-activated and mount a more robust immune response, particularly against cancer cells [4].

6.2 Why a "Potential Immunomodulatory Approach" in PD?

The rationale for using PD-1 inhibitors in PD stems from the increasing evidence linking chronic neuroinflammation to dopaminergic neuronal degeneration. Here's how PD-1 inhibitors might offer an immunomodulatory approach in PD:

Modulating Neuroinflammation:

- Microglial Homeostasis: As discussed, activated microglia are central to neuroinflammation in PD. While PD-1 signaling generally dampens immune responses, its role in the chronically inflamed brain of PD is complex. Some research, particularly in Alzheimer's disease models, suggests that blocking PD-1/PD-L1 signaling on glial cells (microglia and astrocytes) might help shift them

from a harmful, pro-inflammatory state back towards a more "homeostatic" or neuroprotective phenotype. This could involve restoring their ability to clear toxic protein aggregates and reduce the release of neurotoxic inflammatory mediators [4].

- T Cell Modulation: While T cells are less abundant in the healthy brain, their infiltration into the brain is observed in PD. Modulating the activity of these T cells, either by directly reducing their pro-inflammatory actions or by promoting a more regulatory T cell (Treg) response, could reduce overall neuroinflammation (Fig. (2) [4].




Fig. (2). T Cell Modulation

- Restoring Immune Balance: The goal is not to completely suppress the immune system (which could lead to infections or autoimmune issues), but rather to rebalance it towards a less destructive and more protective state within the central nervous system [4].

Potential for Neuroprotection:

- Direct or Indirect Effects: By reducing the toxic inflammatory environment, PD-1 inhibitors might directly protect vulnerable dopaminergic neurons from damage. They could also indirectly promote neuronal survival by enhancing the production of neurotrophic factors or improving cellular waste clearance mechanisms.
- Alpha-Synuclein Clearance: Some studies hypothesize that a modulated immune response could enhance the clearance of misfolded alpha-synuclein, a key pathological protein in PD, thereby reducing its toxicity and preventing its spread [4].

## 7. CURRENT STATUS AND CHALLENGES

The application of PD-1 inhibitors in PD is still in its preclinical or very early clinical investigation stages. Most of the promising data comes from animal models of neurodegenerative diseases, including PD and Alzheimer's disease [4].

7.1 Challenges that need to be addressed include:

- Brain Penetration: While the blood-brain barrier (BBB) can be compromised in neuroinflammatory conditions, ensuring sufficient and targeted delivery of these large antibody molecules to the brain remains a challenge.
- Systemic Side Effects: PD-1 inhibitors can cause significant immune-related adverse events in cancer patients, ranging from skin rashes to severe organ inflammation (colitis, pneumonitis, hepatitis). These risks need to be carefully weighed and managed in a chronic, non-fatal disease like PD.
- Optimal Dosing and Duration: The dosing and duration of treatment might differ significantly from cancer immunotherapy.
- Patient Selection: Identifying which PD patients, perhaps those with specific inflammatory markers or genetic predispositions, would be most likely to benefit from this approach will be crucial.
- Understanding Mechanisms: The precise cellular and molecular mechanisms by which PD-1 blockade might benefit PD are still being elucidated and may be different from their anti-cancer effects [4].

Despite these challenges, the concept of leveraging immunomodulation with PD-1 inhibitors to combat neuroinflammation and potentially slow PD progression offers a novel and exciting therapeutic avenue, moving beyond purely symptomatic treatments. Future research and carefully designed clinical trials will be essential to translate this potential into effective and safe treatments for people with Parkinson's Disease [4].

## 8. PD1 INHIBITORS FOR RESTORING DOPAMINERGIC BALANCE

The potential for PD-1 inhibitors to help restore dopaminergic balance in Parkinson's Disease (PD) is an exciting, albeit still largely theoretical, area of research. It's important to clarify that current PD-1 inhibitors used in cancer are not directly aimed at increasing dopamine production or preventing its breakdown in the same way traditional PD medications do. Instead, their proposed mechanism for impacting dopaminergic balance in PD is indirect, primarily by modulating the neuroinflammatory environment and potentially offering neuroprotection to the vulnerable dopaminergic neurons [4].

Here's how PD-1 inhibitors are hypothesized to contribute to restoring dopaminergic balance:

8.1 By Modulating Neuroinflammation

The loss of dopaminergic neurons in the substantia nigra is central to PD. This loss is significantly exacerbated by chronic neuroinflammation, characterized by activated microglia and infiltrating immune cells that create a toxic environment for neurons.

- Re-balancing Microglial Activity: PD-1 signaling plays a role in regulating microglial activation. While the exact effect of PD-1 blockade on microglia in PD is still being investigated, the hypothesis is that it could help shift microglia from a pro-inflammatory (M1-like) state to a more anti-inflammatory and neuroprotective (M2-like) state. This shift would reduce the release of neurotoxic substances (like pro-inflammatory cytokines, reactive oxygen species) and potentially enhance the microglial capacity to clear harmful aggregates like alpha-synuclein. By reducing this inflammatory insult, the surviving dopaminergic neurons may be better protected, slowing down their degeneration [4].
- Controlling Peripheral Immune Cell Infiltration: In PD, the blood-brain barrier can become leaky, allowing peripheral immune cells (e.g., T cells) to enter the brain and contribute to neuroinflammation. PD-1 inhibitors, by modulating the overall T cell response, might help to regulate the entry and activity of these cells within the CNS, thereby reducing their detrimental effects on dopaminergic neurons [4]

8.2 By Promoting Neuroprotection and Reducing Alpha-Synuclein Pathology

Beyond simply reducing inflammation, PD-1 inhibition might exert more direct or indirect neuroprotective effects that benefit dopaminergic neurons:

- Enhancing Neuronal Survival Pathways: A less inflammatory environment, mediated by PD-1 blockade, could create conditions more favorable for neuronal survival. This might involve the upregulation of neurotrophic factors (like BDNF, which supports neuronal growth and survival) or the activation of cellular repair mechanisms that are otherwise compromised by chronic inflammation and oxidative stress [5].
- Facilitating Alpha-Synuclein Clearance: Alpha-synuclein aggregation is a hallmark of PD and is known to contribute to dopaminergic neuron toxicity and the perpetuation of inflammation. There's a speculative but intriguing possibility that a re-balanced immune response, influenced by PD-1 inhibition, could improve the brain's ability to clear these toxic protein aggregates, either directly through enhanced phagocytic activity of microglia or indirectly by reducing factors that promote aggregation [5].

8.3 Impact on Dopaminergic Balance:

If PD-1 inhibitors can achieve these effects (reducing inflammation, promoting neuroprotection, and aiding alpha-synuclein clearance), the ultimate goal is to:

1. Slow Down Dopaminergic Neuron Loss: By protecting the existing dopamine-producing neurons, PD-1 inhibitors could slow the progression of dopamine depletion.
2. Preserve Dopamine Production: With more healthy dopaminergic neurons surviving, the brain might be able to maintain higher levels of endogenous dopamine for a longer period.
3. Improve Dopaminergic Function: Even if the number of neurons doesn't increase, reducing the inflammatory burden could improve the function of the remaining dopaminergic neurons, potentially leading to better dopamine synthesis, release, and reuptake [6].

This, in theory, would contribute to a better dopaminergic balance by mitigating the primary cause of the imbalance – the progressive loss of dopaminergic neurons.

## 9. CURRENT STATUS AND FUTURE OUTLOOK

It's crucial to reiterate that while the preclinical evidence is promising, the use of PD-1 inhibitors in PD is still largely experimental.

- Preclinical Studies: Much of the evidence comes from in vitro and in vivo animal models of PD, where PD-1 blockade has shown potential in reducing neuroinflammation, protecting dopaminergic neurons, and improving motor deficits.
- Clinical Trials: While PD-1 inhibitors are widely used in oncology, dedicated large-scale clinical trials specifically for PD patients exploring their disease-modifying potential are in very early stages or are being designed. One clinical trial (Biohaven's BHV-8000), mentioned in the search results, is a brain-penetrant TYK2/JAK1 inhibitor, not a direct PD-1 inhibitor, but it targets neuroinflammation, highlighting the broader interest in immunomodulatory approaches in PD. Direct PD-1 inhibitors carry risks of systemic autoimmune side effects, which would need careful consideration for a chronic neurological condition [7].
- Not a Direct Dopamine Replacement: It's important to manage expectations. PD-1 inhibitors are not meant to replace current symptomatic treatments like levodopa, which directly address dopamine deficiency. Instead, they aim to be disease-modifying therapies that could slow or halt the progression of neurodegeneration, potentially reducing the need for high doses of symptomatic medications over time and improving long-term outcomes [7].

The future of PD-1 inhibitors in Parkinson's disease lies in rigorous clinical trials to establish their safety, efficacy, and optimal patient selection, ultimately with the hope of providing a true disease-modifying therapy that can help preserve dopaminergic function and restore balance in the brain.

9.1 Current Status and Future Directions of PD1 Inhibitors for Restoring Dopaminergic Balance

The concept of using PD-1 inhibitors to restore dopaminergic balance in Parkinson's Disease (PD) is an exciting frontier in research, driven by the increasing understanding of neuroinflammation's role in the disease. However, it's crucial to understand that this is still a developing field, with much of the evidence coming from preclinical studies [7].

The use of PD-1 inhibitors specifically for Parkinson's Disease is primarily in the preclinical research phase.

Preclinical Evidence (Animal Models):

- Numerous studies in rodent models of PD (e.g., using MPTP or alpha-synuclein pre-formed fibrils) have shown promising results.
- PD-1 blockade has been observed to:
    - Reduce neuroinflammation by modulating microglial activation (e.g., shifting them towards a more protective phenotype).
    - Protect dopaminergic neurons from degeneration.
    - Improve motor symptoms in these models.
    - Potentially enhance the clearance of pathological alpha-synuclein, a hallmark protein in PD.
- The proposed mechanisms involve rebalancing the immune response within the central nervous system, reducing the chronic inflammatory environment that contributes to neuronal damage [7].

Lack of Widespread Clinical Trials (Direct PD-1 Inhibitors):

- While PD-1 inhibitors (like Nivolumab, Pembrolizumab) are widely used in cancer immunotherapy, there are no large-scale, dedicated Phase II or III clinical trials specifically evaluating direct PD-1 inhibitors for PD as a primary disease-modifying therapy.
- The existing clinical trials for PD focus on a variety of other targets, including:
    - Alpha-synuclein targeting therapies: Antibodies or small molecules aimed at reducing or clearing alpha-synuclein aggregates.
    - Gene therapies: Delivering neurotrophic factors like GDNF to protect neurons.

- Lysosomal function enhancers: Like Ambroxol, which shows promise in improving the clearance of cellular waste, including alpha-synuclein, particularly in individuals with GBA1 mutations.
- NLRP3 inflammasome inhibitors: These directly target a key inflammatory pathway implicated in PD. (For example, drugs like Inzomelid and NT-079 are in clinical trials for this purpose, which aligns with the broader neuroinflammation strategy).
- Other symptomatic treatments: Improving levodopa formulations, new dopamine agonists, etc [7].

Rationale for Caution in Clinical Translation:

- Systemic Immune Side Effects: A major concern is the risk of immune-related adverse events (irAEs) associated with systemic PD-1 blockade. These can range from mild (skin rashes, fatigue) to severe (colitis, pneumonitis, thyroiditis, hepatitis), which could be problematic for a chronic, non-fatal disease like PD where the risk-benefit profile needs to be very carefully balanced.
- Blood-Brain Barrier Penetration: The ability of large antibody molecules (like PD-1 inhibitors) to effectively cross the blood-brain barrier and reach therapeutic concentrations in the relevant brain regions is still a consideration.
- Optimal Targeting: It's unclear if broad systemic PD-1 blockade is the most appropriate strategy for PD. More targeted approaches to modulate neuroinflammation or specific immune cell subsets within the brain might be preferred [8].

9.2 Future Directions

The future directions for PD-1 inhibitors (or similar immunomodulatory approaches) in restoring dopaminergic balance in PD are likely to involve:

More Targeted Immunomodulation:

- Instead of broad systemic PD-1 inhibition, research may focus on more specific ways to modulate the PD-1/PD-L1 pathway or other immune checkpoints. This could include:
  - Small molecule inhibitors: These are typically smaller than antibodies and may have better brain penetrability.
  - Localized delivery: Exploring ways to deliver immunomodulatory agents directly to the brain, bypassing systemic exposure.

- Targeting specific cell types: Developing therapies that preferentially modulate PD-1 signalling on specific immune cells (e.g., microglia) in the brain, rather than broadly affecting all T cells.

- Combinatorial Therapies: Combining immunomodulatory approaches with existing symptomatic treatments or other neuroprotective strategies (e.g., alpha-synuclein-targeting drugs, gene therapies) to achieve synergistic effects [8].

Deepening Understanding of Mechanisms:

- Further research is needed to fully elucidate the precise molecular and cellular mechanisms by which PD-1 signaling influences dopaminergic neuron survival and function in PD. This includes understanding the complex interplay between neurons, glia, and peripheral immune cells.
- Investigating the role of PD-1 in alpha-synuclein aggregation, propagation, and clearance [8].

Biomarker Development:

- Identifying robust biomarkers of neuroinflammation and dopaminergic neuron health will be critical for:
  - Selecting appropriate patients for clinical trials.
  - Monitoring treatment efficacy.
  - Understanding disease progression in response to therapy [8].

Careful Clinical Translation:

- Any future clinical trials for PD-1 inhibitors in PD will need to proceed cautiously, starting with small Phase I safety studies in well-selected patient populations.
- The long-term safety profile and potential for delayed side effects will be paramount.

In conclusion, while direct PD-1 inhibitors are not currently a standard or even widely trialed treatment for PD, the underlying principle of immunomodulation to address neuroinflammation is a major focus in PD research. The future will likely see more refined and targeted approaches that leverage our understanding of the immune system to protect dopaminergic neurons and ultimately restore balance in the Parkinsonian brain [8].

10. Challenges and Considerations:

- Systemic vs. Central Nervous System Effects: PD-1 inhibitors work systemically, and their impact on the complex immune environment of the brain needs careful consideration.

- Autoimmune Risks: Unleashing the immune system carries the risk of inducing autoimmune side effects, which are well-documented in cancer patients receiving these therapies. Managing these risks in a chronic condition like PD will be crucial.
- Patient Selection: Identifying the specific patient populations most likely to benefit from PD-1 inhibitor therapy, perhaps those with a prominent inflammatory component to their disease, will be important.
- Combination Therapies: It's possible that PD-1 inhibitors might be most effective when combined with existing symptomatic treatments or other neuroprotective strategies.

The concept of using PD-1 inhibitors to restore dopaminergic balance in Parkinson's disease is an intriguing and promising area of research. As we gain a deeper understanding of the intricate interplay between the immune system, inflammation, and neurodegeneration in PD, these immunomodulatory therapies may offer a novel approach to not only manage symptoms but potentially modify the disease course. Further rigorous research and clinical trials are essential to determine their true therapeutic potential and safety in PD patients [9].

**CONCLUSION:**

The journey of PD-1 inhibitors in Parkinson's Disease (PD) is an exciting testament to the evolving understanding of neurodegeneration. While these revolutionary cancer immunotherapies are not currently a standard treatment for PD, their potential to restore dopaminergic balance lies in their ability to indirectly address the underlying neuroinflammatory drivers of the disease, rather than directly boosting dopamine levels [9]. In essence, the prevailing hypothesis is that by modulating the chronic, detrimental neuroinflammatory environment in the Parkinsonian brain, PD-1 pathway modulation could:

- Protect remaining dopaminergic neurons: Reducing the toxic inflammatory milieu created by activated microglia and other immune cells may safeguard vulnerable dopamine-producing neurons from further damage and death.
- Slow disease progression: By mitigating neuronal loss, these therapies could potentially slow the rate at which dopamine levels decline, thereby extending the period of effective motor function and delaying symptom worsening.
- Improve neuronal function: A healthier, less inflamed brain environment might allow the surviving dopaminergic neurons to function more efficiently, even if their numbers are not fully restored [9].

However, the path to clinical translation for direct PD-1 inhibitors in PD is fraught with significant challenges:

- Risk-Benefit Balance: The well-documented systemic immune-related adverse events (irAEs) associated with these potent immunotherapies, while acceptable in life-threatening cancers, pose a substantial concern for a chronic, progressive condition like PD.
- Specificity and Delivery: The systemic nature of current PD-1 inhibitors may not be ideal for targeting localized brain inflammation. Research is moving towards more refined approaches that can specifically modulate brain immune responses without broad systemic effects.

Looking ahead, the future of leveraging PD-1 pathway modulation to restore dopaminergic balance in PD will likely involve:

- Precision Immunomodulation: Development of novel agents that more selectively target inflammatory pathways within the brain, potentially through smaller molecules or localized delivery methods, to minimize systemic side effects.
- Combinatorial Strategies: Exploring the synergistic potential of combining immunomodulatory therapies with other promising disease-modifying approaches, such as alpha-synuclein-targeting drugs or gene therapies.
- Robust Biomarker Development: Identifying reliable biomarkers of neuroinflammation and neuronal health to stratify patients, monitor treatment efficacy, and guide personalized therapeutic interventions [9].

In conclusion, PD-1 inhibitors represent a compelling, albeit indirect, avenue for restoring dopaminergic balance in PD by fundamentally altering the neuroinflammatory landscape. While significant research and careful clinical development are still required, the promise of moving beyond mere symptomatic relief to genuinely modifying the disease course by addressing its inflammatory roots offers a beacon of hope for individuals living with Parkinson's Disease [10].

## AUTHORS' CONTRIBUTIONS

The authors confirm their contribution to the paper as follows:

Supervision: S.A.S. and S.S.

Draft manuscript: G.K.

All authors reviewed the results and approved the final version of the manuscript.

## ABBREVIATIONS

- Parkinson's Disease - PD
- Parkinson's disease dementia - PDD

- Magnetic Resonance Imaging - MRI
- Computed Tomography - CT
- Dopamine transporter scan - DAT
- Monoamine Oxidase B- MAO-B
- COMT
- Deep Brain Stimulation - DBS
- Reactive Oxygen Species - ROS
- Nitric Oxide - NO
- Blood-brain barrier - BBB
- Substantia Nigra Pars Compacta - SNpc
- Programmed Death-Ligand 1 - PD-L1

## CONSENT FOR PUBLICATION

Not applicable.

## FUNDING

None.

## CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

## ACKNOWLEDGEMENTS

Authors acknowledge the Principal, Columbia Institute of Pharmacy, Raipur and Management Jan Pragati Education Society for supporting and providing a platform to stand up

## REFERENCES:

1. Trinh, J.; Farrer, M. Advances in the genetics of Parkinson disease. Nat. Rev. Neurol., 2013, 9(8), 445-454. http://dx.doi.org/10.1038/nrneurol.2013.132 PMID: 23857047
2. Paisán-Ruiz, C.; Lewis, P.A.; Singleton, A.B. LRRK2: Cause, risk, and mechanism. J. Parkinsons Dis., 2013, 3(2), 85-103. http://dx.doi.org/10.3233/JPD-130192 PMID: 23938341
3. Gilks, W.P.; Abou-Sleiman, P.M.; Gandhi, S.; Jain, S.; Singleton, A.; Lees, A.J.; Shaw, K.; Bhatia, K.P.; Bonifati, V.; Quinn, N.P.; Lynch, J.; Healy, D.G.; Holton, J.L.; Revesz, T.; Wood, N.W. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet, 2005, 365(9457), 415-416. http://dx.doi.org/10.1016/S0140-6736(05)17830-1 PMID: 15680457
4. Ross, O.A. *et.al*; Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: A case control study. Lancet Neurol., 2011, 10(10), 898-908. http://dx.doi.org/10.1016/S1474-4422(11)70175-2 PMID: 21885347
5. Jaleel, M. *et al*; LRRK2 phosphorylates moesin at threonine-558: Characterization of how Parkin son's disease mutants affect kinase activity. Biochem. J., 2007, 405(2), 307-317. http://dx.doi.org/10.1042/BJ20070209 PMID: 17447891
6. Dzamko, N.; Deak, M.; Hentati, F.; Reith, A.D.; Prescott, A.R.; Alessi, D.R.; Nichols, R.J. Inhibition of LRRK2 ki nase activity leads to dephosphorylation of Ser910/Ser935, disruption

of 14-3-3 binding and altered cytoplasmic locali zation. Biochem. J., 2010, 430(3), 405-413. http://dx.doi.org/10.1042/BJ20100784 PMID: 20659021
7. Guo, L.; Gandhi, P.N.; Wang, W.; Petersen, R.B.; Wilson Delfosse, A.L.; Chen, S.G. The Parkinson's disease associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase thatstimulates kinase activity. Exp. Cell Res., 2007, 313(16), 3658-3670. http://dx.doi.org/10.1016/j.yexcr.2007.07.007 PMID: 17706965
8. West, A.B.; Moore, D.J.; Choi, C.; Andrabi, S.A.; Li, X.; Dikeman, D.; Biskup, S.; Zhang, Z.; Lim, K.L.; Dawson, V.L.; Dawson, T.M. Parkinson's disease-associated muta tions in LRRK2 link enhanced GTP-binding and kinase ac tivities to neuronal toxicity. Hum. Mol. Genet., 2007, 16(2), 223-232. http://dx.doi.org/10.1093/hmg/ddl471 PMID: 17200152
9. Wile, D.J.; Agarwal, P.A.; Schulzer, M.; Mak, E.; Dinelle, K.; Shahinfard, E.; Vafai, N.; Hasegawa, K.; Zhang, J.; McKenzie, J.; Neilson, N.; Strongosky, A.; Uitti, R.J.; Guttman, M.; Zabetian, C.P.; Ding, Y.S.; Adam, M.; Aasly, J.; Wszolek, Z.K.; Farrer, M.; Sossi, V.; Stoessl, A.J. Sero tonin and dopamine transporter PET changes in the premo tor phase of LRRK2 parkinsonism: cross-sectional studies. Lancet Neurol., 2017, 16(5), 351-359. http://dx.doi.org/10.1016/S1474-4422(17)30056-X PMID: 28336296
10. Sosero, Y.L.; Gan-Or, Z. LRRK2 and Parkinson's disease: From genetics to targeted therapy. Ann. Clin. Transl. Neu rol., 2023, 10(6), 850-864. http://dx.doi.org/10.1002/acn3.51776 PMID: 37021623
11. Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Prim. 2017, 3, 17013.
12. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet. 2009, 373, 2055–66.
13. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, Lanciego JL, Artieda J, Gonzalo N, et al. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci. 2000, 23, S8–19.
14. Vu TC, Nutt JG, Holford NH. Progression of motor and nonmotor features of parkinson's disease and their response to treatment. Br J Clin Pharm. 2012;74:267–83.
15. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron. 2003, 39, 889–909.
16. Starkstein SE, Brockman S. Management of depression in Parkinson's disease: a systematic review. Mov Disord Clin Pr. 2017, 4, 470–7.
17. Doty RL. Olfaction in Parkinson's disease and related disorders. Neurobiol Dis. 2012, 46, 527–52.
18. Doty RL. Olfactory dysfunction in Parkinson disease. Nat Rev Neurol. 2012, 8, 329–39.
19. Fox SH. Non-dopaminergic treatments for motor control in Parkinson's disease. Drugs. 2013, 73, 1405–15.
20. Suttrup I, Warnecke T. Dysphagiain Parkinson's disease. Dysphagia. 2016, 31, 24–32.
21. Gratwicke J, Jahanshahi M, Foltynie T. Parkinson's disease dementia: a neural networks perspective. Brain. 2015, 138, 1454–76.
22. Knie B, Mitra MT, Logishetty K, Chaudhuri KR. Excessive daytime sleepiness in patients with Parkinson's disease. CNS Drugs. 2011, 25, 203–12.
23. Sanjari Moghaddam H, Zare-Shahabadi A, Rahmani F, Rezaei N. Neurotransmission systems in Parkinson's disease. Rev Neurosci. 2017, 28, 509–36.
24. Marras C, Chaudhuri KR. Nonmotor features of Parkinson's disease subtypes. Mov Disord. 2016, 31, 1095–102.
25. Cheong SL, Federico S, Spalluto G, Klotz KN, Pastorin G. The current status of pharmacotherapy for the treatment of Parkinson's disease: transition from single-target to multitarget therapy. Drug Discov Today. 2019, 24, 1769–83.
26. Ellis JM, Fell MJ. Current approaches to the treatment of Parkinson's disease. Bioorg Med Chem Lett. 2017, 27, 4247–55.
27. Kulisevsky J, Oliveira L, Fox SH. Update in therapeutic strategies for Parkinson's disease. Curr Opin Neurol. 2018, 31, 439–47.
28. Smith Y, Wichmann T, Factor SA, DeLong MR. Parkinson's disease therapeutics new developments and challenges since the introduction of levodopa. Neuropsychopharmacology. 2012, 37, 213–46.
29. Freitas ME, Fox SH. Nondopaminergic treatments for Parkinson's disease: current and future prospects. Neurodegener Dis Manag. 2016, 6, 249–68.

30. Chaudhuri KR, Healy DG, Schapira AH.National Institute for Clinical Excellence Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 2006, 5, 235–45.
31. Stayte S, Vissel B. Advances in non-dopaminergic treatments for Parkinson's disease. Front Neurosci. 2014, 8, 113.
32. Muller T. Current and investigational non-dopaminergic agents for management of motor symptoms (including motor complications) in Parkinson's disease. Expert Opin Pharmacother. 2017, 18, 1457–65.
33. Vanle B, Olcott W, Jimenez J, Bashmi L, Danovitch I, IsHak WW. NMDA antagonists for treating the non-motor symptoms in Parkinson's disease. Trans Psychiatry. 2018, 8, 117.
34. Kalia LV, Brotchie JM, Fox SH. Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials. Mov Disord. 2013, 28, 131–44.
35. Guo L, Zhen X. Sigma-2 receptor ligands: neurobiological effects. Curr Med Chem. 2015, 22, 989–1003.
36. Zheng J, Zhang X, Zhen X. Development of adenosine a2a receptor antagonist for the treatment of Parkinson's disease: a recent update and challenge. ACS Chem Neurosci. 2019, 10, 783–91.
37. Pinna A. Adenosine a2a receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued. CNS Drugs. 2014, 28, 455–74.
38. Cacciari B, Spalluto G, Federico S. A2a adenosine receptor antagonists as therapeutic candidates: are they still an interesting challenge? Mini Rev Med Chem. 2018, 18, 1168–74.
39. de Lera Ruiz M, Lim YH, Zheng J. Adenosine a2a receptor as a drug discovery target. J Med Chem. 2014, 57, 3623–50.
40. Katzenschlager R, Sampaio C, Costa J, Lees A Anticholinergics for symptomatic management of parkinson's disease. Cochrane Database Syst. Rev. 2003, CD003735.